Hospital Vithas Xanit Internacional

Benalmadena 19 trials 8 recruiting

19 Registered trials

8 Currently recruiting

Organisation

Hospital Vithas Xanit Internacional

Location

Benalmadena, Spain

Identifier

ORG-100046069

Address

Avenida De Los Argonautas S/N, 29639, Spain

Departments

5515: Pneumology
7004: Pneumology
7007_Pneumology
7008: Pneumology
Hospital Vithas Xanit Internacional
Infectious Disease
Neumología
Neumology
Pediatria
Pneumology
Pneumology Department
Respiratory Unit

Clinical trials at this site (19)

Search interface

A study to evaluate the efficacy, immunogenicity, and safety of an RSV and hMPV VLP vaccine compared with placebo in participants aged 60 ye… Pending

2024-513740-28-00 Respiratory Syncytial Virus and Human Metapneumovirus 5
BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/… Pending

2025-524289-56-00 Asthma 6
Long-term safety and efficacy evaluation of lunsekimig (SAR443765) in adult participants with moderate-to-severe asthma. Recruiting

2025-522896-27-00 Asthma 4 2026-05-11
A trial to learn how well AZD0292 works, how safe it is, and how it moves throughout the body over time in people with bronchiectasis and ch… Recruiting

2025-523009-14-00 Bronchiectasis with chronic pseudomonas aeruginosa colo 4 2025-12-16
A Phase 2 Randomized, Double-blind Placebo-Controlled Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety and Efficacy of WIN378 … Recruiting

2025-521391-58-00 Asthma 4 2025-11-28
A phase 3b study of depemokimab on airway structure and function in patients with type 2 asthma utilizing quantitative high-resolution CT an… Recruiting

2024-519976-19-00 Asthma with type 2 inflammation characterized by an eos 5 2025-11-26
A study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease Recruiting

2025-520473-40-00 Moderate to Very Severe Chronic Obstructive Pulmonary D 4 2025-09-29
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients with Coronavirus Disease 2019 (COVID-19) who ar… Recruiting

2024-517727-39-00 Covid-19 at high risk of progression to severe illness. 5 2025-07-28
Study of lunsekimig (SAR443765) compared with placebo in adults with high-risk asthma Recruiting

2024-513959-33-00 Asthma 4 2025-05-13
A study to assess efficacy and safety of benralizumab in paediatric patients with severe eosinophilic asthma (severe asthma marked by high… Recruiting

2022-501344-14-00 Paediatric Patients with Severe Eosinophilic Asthma Ast 5 2023-06-05
Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended

2025-520488-42-00 Moderate-to-Severe Chronic Obstructive Pulmonary Diseas 4 2025-09-17
A dose finding study with an anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma. Ended

2024-518321-15-00 Asthma 4 2025-05-30
A trial to learn how safe AZD8630 is and how well it works in adults with uncontrolled asthma. Ended

2024-514228-18-00 Asthma in adults who remain uncontrolled despite medium 4 2025-01-16
A study to assess and compare safety and tolerability of 3 months treatment with salbutamol administered via MDI containing propellant HFA-1… Ended

2023-509001-76-00 Asthma 5 2024-07-01
A Study to Evaluate the Effect of BGF MDI, BFF MDI and Placebo MDI on Exercise Parameters in Participants with COPD Ended

2022-502274-16-00 Chronic Obstructive Pulmonary Disease 11 2023-10-19
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended

2022-502234-70-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-07-14
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twel… Ended

2023-509243-27-00 Moderate-to-Severe Uncontrolled Asthma 4 2023-04-12
A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended

2023-505203-23-01 Severe asthma with an eosinophilic phenotype 5 2021-07-26
Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin… Ended

2023-510230-84-00 Severe asthma with an eosinophilic phenotype 5 2021-05-28